However, the specificity of RNF7 knockdown, the effects on STAT3 activity, and a triple combination therapy of sunitinib, STAT3 inhibition, and RNF7 knockdown on regulating tumor growth in vivo need to be investigated further. The gene discussed is STAT3; the disease is neoplasm.